Alnylam Pharmaceuticals has announced the final results from its completed Phase 1 clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
ALN-TTR01 is a systemically delivered RNAi therapeutic that employs first-generation lipid nanoparticle (LNP) technology.
Go deeper with GlobalData
In the randomised, placebo-controlled, single-dose escalation Phase 1 study, patients with ATTR were enrolled in seven sequential cohorts of increasing doses ranging from 0.01mg/kg to 1mg/kg.
The study data demonstrated that administration of ALN-TTR01 resulted in considerable reductions in serum TTR protein levels, including both wild-type and mutant TTR protein, in ATTR patients.
ALN-TTR01 also showed a dose-dependent reduction in serum TTR levels, with a mean reduction of 38% at approximately day 7 to 10 in the 1mg/kg group.
Jared Gollob, Alnylam Pharmaceuticals’ clinical research senior director, said the Phase 1 data from the ALN-TTR01 clinical study demonstrates rapid, dose-dependent and durable lowering of TTR protein levels after a single dose in ATTR patients.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData"Further, the full-time course for TTR knockdown after a single dose confirms our expectations for a once a month, or possibly even a once every two month, dosing regimen in our further studies," Gollob added.
"We believe these data with ALN-TTR01 provide key human proof of concept, as we advance ALN-TTR02 as our ‘go-to-market’ RNAi therapeutic for the treatment of ATTR, a debilitating orphan genetic disease."
Alnylam is also developing ALN-TTR02, which utilises second-generation LNP delivery technology and is currently being tested in a Phase 1 clinical study for the treatment of ATTR.
The Phase 1 data from ALN-TTR02 trial is expected to be announced in the third quarter of 2012.
The company is also planning to commence a Phase 2 multi-dose study of ALN-TTR02 in the second half of 2012 and, supposing positive results, anticipates beginning a pivotal trial for ALN-TTR02 in 2013.
